Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials

Qureight , an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 million in a Series B financing, led by Molten Ventures . Existing investors Hargreave Hale AIM VCT , XTX Ventures, Guinness Ventures , Meltwind, and Ascension also participated in the round. This brings the company's funding to over €27 million.